SAB Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.11	1.32	2.24	23.9	60.88	55.24
Revenue Growth (YoY)	-92.42%	-40.94%	-90.63%	-60.73%	10.21%	1504.91%
Gross Profit	0.11	1.32	2.24	23.9	60.88	55.24
Selling, General & Admin	12.03	13.98	23.8	16.38	17.09	6.77
Research & Development	31.28	30.25	16.52	36.44	57.18	27.91
Total Operating Expenses	43.31	44.23	40.31	52.82	74.27	34.68
Operating Income	-43.19	-42.91	-38.08	-28.92	-13.39	20.56
Total Non-Operating Income (Expense)	61.93	8.81	-4.12	10.2	-	-
Pretax Income	18.74	-34.11	-42.19	-18.72	-13.39	20.56
Provision for Income Taxes	-	-	-	-0.03	-	-
Net Income	19.26	-34.11	-42.19	-18.74	-17.14	20.12
Net Income to Common	19.26	-34.11	-42.19	-18.74	-17.14	20.12
Shares Outstanding (Basic)	10	9	6	4	3	3
Shares Outstanding (Diluted)	26	9	6	4	3	3
Shares Change (YoY)	110.62%	67.74%	26.86%	59.20%	1.21%	9.60%
EPS (Basic)	-2.38	-3.68	-7.64	-4.31	-6.30	7.90
EPS (Diluted)	-3.09	-3.68	-7.64	-4.31	-6.30	7.40
Free Cash Flow	-37.59	-34.63	-25.32	-25.63	-8.96	-2.73
Free Cash Flow Per Share	-1.42	-3.74	-4.59	-5.89	-3.28	-1.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-37657.13%	-3244.87%	-1700.56%	-120.97%	-22.00%	37.22%
Profit Margin	16338.32%	-2579.03%	-1884.50%	-78.19%	-22.00%	37.22%
FCF Margin	-32769.84%	-2618.65%	-1130.71%	-107.20%	-14.71%	-4.94%
EBITDA	-40.09	-38.12	-34.33	-25.63	-11.74	21.1
EBITDA Margin	-34950.89%	-2882.46%	-1533.28%	-107.20%	-19.28%	38.21%
EBIT	-43.19	-42.91	-38.08	-28.92	-13.39	20.56
EBIT Margin	-37657.13%	-3244.87%	-1700.56%	-120.97%	-22.00%	37.22%
Effective Tax Rate	-	0.00%	0.00%	0.14%	0.00%	0.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q